{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:05:49Z","timestamp":1784264749872,"version":"3.55.0"},"reference-count":38,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Quantitative PCR measurement of BCR::ABL1 is essential for monitoring molecular response and detecting relapse in chronic myeloid leukemia (CML) patients. Given the availability of multiple commercial kits for cDNA synthesis and minimal residual disease assessment, analytical accuracy and reliability are critical. This study evaluated two commercial RT and qPCR kits for BCR::ABL1 quantification and fusion transcript variant identification. Methods: Total RNA was isolated from peripheral blood, bone marrow, and external quality control samples from the UK NEQAS for Leucocyte Immunophenotyping program. cDNA synthesis was performed using two kits: AffinityScript (ASK) and RT Kit (RTK). BCR::ABL1 transcript levels were determined using the ipsogen\u00ae BCR-ABL1 Mbcr IS-MMR Kit (IPS) and the LightMix\u00ae bcr-abl t(9;22) M\/m\/\u00b5 Kit (TMB). Results were compared with UK NEQAS LI reference data. Fusion transcript variants were analyzed using nested PCR and a commercial qPCR assay. Results: Substantial variability was observed between the TMB and IPS assays, with moderate, non-significant correlation and wide limits of agreement. Established discrepancies resulted in different classifications of molecular response, and IPS results showed better concordance with external quality assessment data. ABL1 quantification revealed significantly higher copy numbers with the RTK compared to the ASK (p &lt; 0.0001), enabling more reliable assessment of deep molecular responses. Statistical analyses indicated systematic and proportional bias between the methods. For variant detection, nested PCR demonstrated higher specificity, while the commercial assay showed limited discriminatory capability. Conclusions: Significant methodological differences may affect clinical interpretation, underscoring the importance of validation and standardization in CML molecular monitoring.<\/jats:p>","DOI":"10.3390\/diagnostics16142216","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:05:07Z","timestamp":1784163907000},"page":"2216","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice in BCR::ABL1 Testing for Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5418-3178","authenticated-orcid":false,"given":"Mirjana","family":"Suver Stevi\u0107","sequence":"first","affiliation":[{"name":"University Hospital Center Osijek, Josipa Huttlera 4, HR-31000 Osijek, Croatia"},{"name":"Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, HR-31000 Osijek, Croatia"},{"name":"Department of Biology, Josip Juraj Strossmayer University of Osijek, HR-31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4801-1270","authenticated-orcid":false,"given":"Vlatka","family":"Peri\u0161a","sequence":"additional","affiliation":[{"name":"University Hospital Center Osijek, Josipa Huttlera 4, HR-31000 Osijek, Croatia"},{"name":"Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, HR-31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Vuji\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Biology, Josip Juraj Strossmayer University of Osijek, HR-31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161ka","family":"Marczi","sequence":"additional","affiliation":[{"name":"University Hospital Center Osijek, Josipa Huttlera 4, HR-31000 Osijek, Croatia"},{"name":"Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, HR-31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasminka","family":"Sin\u010di\u0107-Petri\u010devi\u0107","sequence":"additional","affiliation":[{"name":"University Hospital Center Osijek, Josipa Huttlera 4, HR-31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Mjeda","sequence":"additional","affiliation":[{"name":"University Hospital Center Osijek, Josipa Huttlera 4, HR-31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1017\/pcm.2023.9","article-title":"Targeting BCR-ABL1-positive leukaemias: A review article","volume":"1","author":"Leak","year":"2023","journal-title":"Camb. Prism. Precis. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41586-025-08817-2","article-title":"Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia","volume":"640","author":"Kamizela","year":"2025","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cytogfr.2025.05.001","article-title":"BCR-ABL: The molecular mastermind behind chronic myeloid leukemia","volume":"83","author":"Shammas","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Amarante-Mendes, G.P., Rana, A., Datoguia, T.S., Hamerschlak, N., and Brumatti, G. (2022). BCR-ABL1 tyrosine kinase complex signaling transduction: Challenges to overcome resistance in chronic myeloid leukemia. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010215"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular Pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106156","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","article-title":"Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review","volume":"12","author":"Sampaio","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e35953","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023\u2014Common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease","volume":"13","author":"Macintyre","year":"1999","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjh.14557","article-title":"Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: Findings from an International EQA Programme","volume":"177","author":"Scott","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Izzo, B., Gottardi, E.M., Errichiello, S., Daraio, F., Barat\u00e8, C., and Galimberti, S. (2019). Monitoring chronic myeloid leukemia: How molecular tools may drive therapeutic approaches. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00833"},{"key":"ref_17","unstructured":"(2024, April 13). ACMG Technical Lab Standards Section G.pdf. Available online: https:\/\/www.acmg.net\/PDFLibrary\/ACMG%20Technical%20Lab%20Standards%20Section%20G.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41375-022-01607-z","article-title":"Standardization of molecular monitoring of CML: Results and recommendations from the European treatment and outcome study","volume":"36","author":"White","year":"2022","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Spiess, B., Rinaldetti, S., Naumann, N., Galuschek, N., Kossak-Roth, U., Wuchter, P., Tarnopolscaia, I., Rose, D., Voskanyan, A., and Fabarius, A. (2019). Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214305"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Dumitru, I.G., Todor, S.B., Ichim, C., Helgiu, C., and Helgiu, A. (2025). A literature review on the impact of the gut microbiome on cancer treatment efficacy, disease evolution and toxicity: The implications for hematological malignancies. J. Clin. Med., 14.","DOI":"10.3390\/jcm14092982"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Guevara-Ram\u00edrez, P., Cadena-Ullauri, S., Paz-Cruz, E., Tamayo-Trujillo, R., Ruiz-Pozo, V.A., and Zambrano, A.K. (2023). Role of the gut microbiota in hematologic cancer. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1185787"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e00538","DOI":"10.1016\/j.plabm.2026.e00538","article-title":"Analytical performance evaluation and method comparison of the 1copy BCR::ABL1 qPCR assay for monitoring chronic myeloid leukemia","volume":"50","author":"Hyerin","year":"2026","journal-title":"Pract. Lab. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Costanza Danzero, A., Gottardi, E.M., Quarantelli, F., Del Prete, C., Potenza, A., Venturi, C., Berchialla, P., Guerrini, F., Bono, C., and Ottaviani, E. (2025). An automated cartridge-based microfluidic system for real-time quantification of BCR::ABL1 transcripts in chronic myeloid leukemia: An Italian experience. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26188932"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12575-015-0014-x","article-title":"cDNA synthesis for BCR-ABL1 detection at the MMR level: The importance of using the appropriate kit","volume":"17","author":"Chi","year":"2015","journal-title":"Biol. Proced. Online"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Spiess, B., Kleiner, H., Tarnopolscaia, I., Naumann, N., Fabarius, A., Hofmann, W.K., Saussele, S., and Seifarth, W. (2023). Reverse transcription can critically impact the diagnostic outcome of BCR::ABL1 quantitative real-time RT-PCR. Cancers, 15.","DOI":"10.3390\/cancers15153914"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjh.15542","article-title":"Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK","volume":"182","author":"Cross","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"841546","DOI":"10.3389\/fonc.2022.841546","article-title":"Impact of BCR-ABL1 transcript type on outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A pairwise and bayesian network meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1111\/cas.15501","article-title":"Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia","volume":"113","author":"Su","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-022-01612-2","article-title":"Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy","volume":"36","author":"Salmon","year":"2022","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.18632\/oncotarget.27652","article-title":"Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib","volume":"11","author":"Genthon","year":"2020","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s40064-015-0930-x","article-title":"Coexistence of P190 and P210 BCR\/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib","volume":"4","author":"Zhao","year":"2015","journal-title":"SpringerPlus"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","article-title":"No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: Results in 1494 patients with chronic myeloid leukemia treated with imatinib","volume":"143","author":"Pfirrmann","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bjhh.2014.07.024","article-title":"A case of chronic myeloid leukemia with the m-bcr (p190) molecular rearrangement identified during treatment","volume":"37","author":"Asinari","year":"2015","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5045\/br.2018.53.2.152","article-title":"The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML)","volume":"53","author":"Horvat","year":"2018","journal-title":"Blood Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1590\/S1415-47572007000400003","article-title":"An analysis of multiplex-PCR in the detection of BCR-ABL transcripts in hematological disorders","volume":"30","author":"Sastre","year":"2007","journal-title":"Genet. Mol. Biol."},{"key":"ref_38","first-page":"65","article-title":"BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran","volume":"9","author":"Ayatollahi","year":"2018","journal-title":"Casp. J. Intern. Med."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/14\/2216\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:26:19Z","timestamp":1784262379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/14\/2216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":38,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["diagnostics16142216"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16142216","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}